INSMED INC Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
INSMED INC (INSM) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $8.30 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $8.30M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $8.30M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $7.20M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $5.10M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $8.30M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $8.30M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $7.20M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $5.10M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.10M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $5.10M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $5.10M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $5.10M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $5.10M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $5.10M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $5.10M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $5.10M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $5.10M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $5.10M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $5.10M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $5.10M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $5.10M 10-Q · filed 2021-05-06 |
| 2020-09-30 | $5.00M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $5.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.00M 10-Q · filed 2020-04-30 |
| 2019-09-30 | $5.00M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $5.00M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $5.00M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |